These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 37144780)
1. Solamargine enhanced gefitinib antitumor effect via regulating MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway in non-small cell lung cancer. Tang Q; Zhou Q; Li J; Yang X; Wang R; Wang X; Xu M; Han L; Wu W; Wang S Carcinogenesis; 2023 Aug; 44(6):497-510. PubMed ID: 37144780 [TBL] [Abstract][Full Text] [Related]
2. Combination of Solamargine and Metformin Strengthens IGFBP1 Gene Expression Through Inactivation of Stat3 and Reciprocal Interaction Between FOXO3a and SP1. Tang Q; Zheng F; Wu J; Xiao Q; Li L; Hann SS Cell Physiol Biochem; 2017; 43(6):2310-2326. PubMed ID: 29073599 [TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3. Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264 [TBL] [Abstract][Full Text] [Related]
4. LncRNA MALAT1 Depressed Chemo-Sensitivity of NSCLC Cells through Directly Functioning on miR-197-3p/p120 Catenin Axis. Yang T; Li H; Chen T; Ren H; Shi P; Chen M Mol Cells; 2019 Mar; 42(3):270-283. PubMed ID: 30841025 [TBL] [Abstract][Full Text] [Related]
5. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process. Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760 [TBL] [Abstract][Full Text] [Related]
6. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer. Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611 [TBL] [Abstract][Full Text] [Related]
7. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5. Li Q; Wang Y; He J J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242 [TBL] [Abstract][Full Text] [Related]
8. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer. Ge P; Cao L; Chen X; Jing R; Yue W BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748 [TBL] [Abstract][Full Text] [Related]
9. Exosomal long non-coding RNA SOX2 overlapping transcript enhances the resistance to EGFR-TKIs in non-small cell lung cancer cell line H1975. Zhou D; Xia Z; Xie M; Gao Y; Yu Q; He B Hum Cell; 2021 Sep; 34(5):1478-1489. PubMed ID: 34244990 [TBL] [Abstract][Full Text] [Related]
10. SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3p. Wu K; Li J; Qi Y; Zhang C; Zhu D; Liu D; Zhao S Biomed Pharmacother; 2019 Aug; 116():108995. PubMed ID: 31121484 [TBL] [Abstract][Full Text] [Related]
11. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells. Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757 [TBL] [Abstract][Full Text] [Related]
12. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death. Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210 [TBL] [Abstract][Full Text] [Related]
13. Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p. Ma G; Zhu J; Liu F; Yang Y DNA Cell Biol; 2019 Feb; 38(2):176-183. PubMed ID: 30601026 [TBL] [Abstract][Full Text] [Related]
14. The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC. Li X; Zhang X; Yang C; Cui S; Shen Q; Xu S Cell Cycle; 2018; 17(14):1772-1783. PubMed ID: 30010468 [TBL] [Abstract][Full Text] [Related]
15. FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma. Tang Q; Xu M; Long S; Yu Y; Ma C; Wang R; Li J; Wang X; Fang F; Han L; Wu W; Wang S J Ethnopharmacol; 2024 Jan; 318(Pt A):116646. PubMed ID: 37269912 [TBL] [Abstract][Full Text] [Related]
16. Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression. Pan Z; Wang K; Wang X; Jia Z; Yang Y; Duan Y; Huang L; Wu ZX; Zhang JY; Ding X Mol Cancer; 2022 Mar; 21(1):77. PubMed ID: 35303882 [TBL] [Abstract][Full Text] [Related]
17. HDAC1 and FOXK1 mediate EGFR-TKI resistance of non-small cell lung cancer through miR-33a silencing. Liu J; Wang W; Wang K; Liu W; Zhao Y; Han X; Wang L; Jiang BH J Transl Med; 2024 Aug; 22(1):793. PubMed ID: 39198847 [TBL] [Abstract][Full Text] [Related]
18. Reciprocal interaction of HOTAIR and SP1 together enhance the ability of Xiaoji decoction and gefitinib to inhibit EP4 expression. Wu J; Tang Q; Ren X; Zheng F; He C; Chai X; Li L; Hann SS J Ethnopharmacol; 2019 Jun; 237():128-140. PubMed ID: 30910577 [TBL] [Abstract][Full Text] [Related]
19. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. Park KS; Raffeld M; Moon YW; Xi L; Bianco C; Pham T; Lee LC; Mitsudomi T; Yatabe Y; Okamoto I; Subramaniam D; Mok T; Rosell R; Luo J; Salomon DS; Wang Y; Giaccone G J Clin Invest; 2014 Jul; 124(7):3003-15. PubMed ID: 24911146 [TBL] [Abstract][Full Text] [Related]
20. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT. Jiao D; Chen J; Li Y; Tang X; Wang J; Xu W; Song J; Li Y; Tao H; Chen Q J Cell Mol Med; 2018 Jul; 22(7):3526-3536. PubMed ID: 29664235 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]